Research and development is a fundamental part of the way diseases are treated.
Devastating conditions like AIDS are no longer the death sentence that they were thanks to the innovative, free-market approach that has incentivized pharmaceutical companies to develop therapies.
House Democrats’ push to include price controls in their tax-and-spend legislation will send shocks throughout our health care system and will lead to reduced treatments and therapies on the market.
That’s not all: the Democrats’ reconciliation bill gives the Secretary of Health and Human Services unilateral authority to set the prices of drugs, with no accountability or oversight. This will lead to out-of-touch bureaucrats in Washington dictating the pharmaceutical products that America’s seniors and patients take, which will undermine the existing doctor-patient relationship.
By purposefully misleading the American public on what their bill will do and ramming their legislation through the House without proper scoring from the Congressional Budget Office, it’s clear that Speaker Pelosi is up to the same budgetary tricks and gimmicks that she was using in 2009 — and that her mantra is still “We have to pass the bill so that you can find out what is in it.”
House Republican Leader Kevin McCarthy (CA-23) has been hosting a series of roundtables to elucidate what’s in the Democrats’ reckless spending bill. Previous roundtables have covered some of the important provisions that Democrats don’t want the public to hear the consequences of: provisions like the IRS spying on just about everyone’s bank accounts, provisions making it more expensive for Americans to heat their home and fill the tank in their cars, and provisions boxing parents out of their child’s education.
House Energy and Commerce Ranking Member Cathy McMorris Rodgers (WA-05) led the ninth roundtable series on the Democrats’ reconciliation bill, where she is demonstrating the effect that socialized medicine will have on America. Joining her are Representatives Rep. Brad Wenstrup (OH-02), Rep. Diana Harshbarger (TN-01), Rep. Mariannette Miller-Meeks (IA-02), and Rep. Adrian Smith (NE-03). They were also joined by guests John Crowley, Chairman and CEO of Amicus Therapeutics; Joel White, with the Council for Affordable Health Coverage; Vivek Ramaswamy, a health care and technology entrepreneur; and Colonel Vladimir Berkovich, Medical Doctor.
Ranking Member McMorris Rodgers: “Rather than lurch toward socialist price controls, we should secure America’s leadership as the best place in the world to save lives, and raise our standard of living. WIth bipartisan solutions that are included in our legislation H.R. 19 — the Lower Costs, More Cures Act, that’s how we win the future.”
Rep. Wenstrup: “You look at something like [new treatments] that save you in the long run. It may cost a little bit more for the medicine now, but you are not paying for all the problems you would be developing otherwise.”
Rep. Harshbarger: “The primary stakeholder is the patient and that patient is who we are concerned about… Physicians prescribe certain medications and they have to go through the prior-approval process over and over in testing three or four drug therapies before they get on the one that works for that patient.”
Rep. Miller-Meeks: “Drug prices are important. We need to talk about the whole supply chain of drug prices to increase competition, not reduce innovation. Americans get 96% of the new drugs that cure diseases. I think that’s what Americans are interested in.”
Rep. Smith: “Democrats want price control and overall more control over our health care and individuals as a whole.”
John Crowley, Chairman and CEO of Amicus Therapeutics: “I’m really concerned about the legislation here that’s being proposed. It’s not only going to immediately harm people, I believe it will be a mistake for the ages.”
Joel White, with the Council for Affordable Health Coverage: “We all want lower costs. We all want more access to affordable coverage.”
Vivek Ramaswamy, health care and technology entrepreneur: “The United States is subsidizing the cost of developing drugs globally… If the pricing of a life-saving drug were going to be the same in the United States as in Europe or other parts of the world, I can tell you that in a majority of cases we would not have proceeded with the development of that medicine.”
Col. Vladimir Berkovich, Medical Doctor: “When we talk about price control we start talking about government control and most important government planning something, which was done in the former Soviet Union…it’s not sustainable.”